Recently, Gagne et al., reported that olmesartan use is associated with enteropathy (paper and news article ) .
Olmesartan, the angiotensin II receptor blocker (ARB), has been widely used to manage cardiovascular diseases including hypertension since its approval in 2002 with estimated worldwide sales of US $2 billion in 2009.
Mini-Sentinel project focused on the association between olmesartan and enteropathy, too. After this, the United States Federal Drug Administration changed the olmesartan medoxomil combination label to include warnings of sprue-like enteropathy.
But I found that olmesartan is not associated with the risk of enteropathy in Korean population (paper). The different HLA haplotypes among races can be one cause of this difference.
So, it will be interesting to replicate Gagne's paper, Basson's paper (the first population level estimation paper for this association) or my paper to demonstrate association between olmesartan and enteropathy across the world.
Is there anyone who want to join this study?